Chronic Pulmonary Infections - Pipeline Insight, 2024

This “Chronic Pulmonary Infections - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Chronic Pulmonary Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Pulmonary Infections: Understanding

Chronic Pulmonary Infections: Overview

Chronic pulmonary infections are long-lasting infections of the lungs that persist for weeks, months, or even years. Unlike acute infections, these conditions are slow-progressing and often resistant to treatment, requiring long-term management. Common causes include bacteria (like Mycobacterium tuberculosis or Pseudomonas aeruginosa), fungi (such as Aspergillus species), and viruses in some cases. Chronic infections may arise due to an underlying condition like chronic obstructive pulmonary disease (COPD), cystic fibrosis, or weakened immunity. Without timely and effective treatment, these infections can cause permanent lung damage and impair respiratory function. The signs and symptoms of chronic pulmonary infections are often similar to those of acute infections but more persistent and severe. Patients may experience a chronic productive cough, sometimes accompanied by blood-tinged sputum, shortness of breath, fatigue, and chest pain. Fever, night sweats, and weight loss are also common, particularly in cases like tuberculosis. Over time, symptoms can worsen as the infection spreads, potentially leading to bronchiectasis (permanent airway dilation) or abscess formation within the lungs. The chronic nature of these infections means that symptoms fluctuate, with periods of worsening (exacerbations) followed by relative relief.

Chronic pulmonary infections are caused by a variety of pathogens that evade or overwhelm the body's immune defenses. Common bacterial culprits include Mycobacterium tuberculosis (tuberculosis), Nontuberculous mycobacteria (NTM), and Pseudomonas aeruginosa - the latter being common in cystic fibrosis patients. Fungal infections like Aspergillosis and Histoplasmosis can also lead to chronic lung disease, particularly in immunocompromised individuals. These pathogens may persist due to inadequate immune responses, leading to inflammation, tissue damage, and the development of fibrotic lung tissue, which traps the infection and exacerbates lung function decline over time.

Diagnosis of chronic pulmonary infections involves a combination of clinical evaluation, imaging studies, and laboratory tests. A chest X-ray or CT scan often reveals characteristic patterns such as cavitations, nodules, or bronchiectasis. Microbiological testing is critical for identifying the specific pathogen involved, which typically involves sputum cultures, bronchoscopy samples, or blood tests. Molecular methods like polymerase chain reaction (PCR) can detect the genetic material of certain pathogens quickly. For infections like tuberculosis, skin tests or interferon-gamma release assays (IGRAs) are used to confirm infection. Fungal infections may require antigen or antibody testing, depending on the suspected pathogen.

Treatment of chronic pulmonary infections is often long-term and depends on the causative agent. For bacterial infections like tuberculosis, a prolonged course of antibiotics (6-12 months) is required, often involving multiple drugs to prevent resistance. Infections with Pseudomonas or NTM may require inhaled or intravenous antibiotics, often combined with therapies to clear mucus from the lungs. Fungal infections are treated with antifungal medications such as itraconazole or amphotericin B. In cases where the infection is unresponsive to medical therapy, surgical intervention to remove damaged lung tissue may be considered. Managing underlying conditions (like COPD or cystic fibrosis) and ensuring good pulmonary hygiene, including physiotherapy, are also critical components of long-term care.

"Chronic Pulmonary Infections - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Pulmonary Infections pipeline landscape is provided which includes the disease overview and Chronic Pulmonary Infections treatment guidelines. The assessment part of the report embraces, in depth Chronic Pulmonary Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Pulmonary Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Pulmonary Infections R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Pulmonary Infections.

Chronic Pulmonary Infections Emerging Drugs Chapters

This segment of the Chronic Pulmonary Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Pulmonary Infections Emerging Drugs

Tanimilast: Chiesi Farmaceutici

Tanimilast (CHF6001), developed by Chiesi Farmaceutici, is a novel inhaled phosphodiesterase 4 (PDE4) inhibitor aimed at treating chronic inflammatory lung diseases, particularly COPD and asthma. It works by reducing inflammation in the airways, helping to manage symptoms like exacerbations in chronic pulmonary conditions. Tanimilast has shown promise in clinical trials for improving lung function and reducing exacerbations in COPD patients, making it a potential treatment for chronic pulmonary infections exacerbated by underlying inflammatory disorders. The drug is currently under Phase III stage of development for the treatment of chronic pulmonary infections.

AP-PA02: Armata Pharmaceuticals

AP-PA02 is a novel therapeutic phage cocktail that targets the pathogen P. aeruginosa, to treat serious respiratory infections. AP-PA02 is comprised of a cocktail of natural P. aeruginosa phages originating from distinct families and subfamilies, targeting multiple receptor classes, functioning with compatibility and cooperativity, and further characterized by being highly potent and having a broad host range. AP-PA02 is developed as a sterile liquid formulation, suitable for delivery by inhalation. Clinical trial material of AP-PA02 is manufactured under cGMP at Armata’s production facility in California. Currently, the drug is in the Phase II stage of its development for the treatment of Chronic Pulmonary Infections.

Chronic Pulmonary Infections: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Pulmonary Infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Pulmonary Infections

There are approx. 10+ key companies which are developing the therapies for Chronic Pulmonary Infections. The companies which have their Chronic Pulmonary Infections drug candidates in the most advanced stage, i.e. Phase III include, Chiesi Farmaceutici.

Phases

The report covers around 15+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of:
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chronic Pulmonary Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as:

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Pulmonary Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Pulmonary Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Pulmonary Infections drugs.

Chronic Pulmonary Infections Report Insights

• Chronic Pulmonary Infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Pulmonary Infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Pulmonary Infections drugs?
• How many Chronic Pulmonary Infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Pulmonary Infections?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Pulmonary Infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Pulmonary Infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Chiesi Farmaceutici
• Armata Pharmaceuticals
• Genentech
• Altesa Biosciences
• Kinaset Therapeutics
• Apogee Therapeutics

Key Products

• Tanimilast
• AP-PA02
• Astegolimab
• Vapendavir
• KN-002
• APG808

This product will be delivered within 2 business days.